Netherlands Discussion Group
The Netherlands Area Biotech (NLab) Discussion Group is the first CASSS discussion group located outside the US and is intended to enable the local area community of industry, academic, and regulatory professionals to meet and share ideas and experiences, thereby working together to resolve scientific challenges in the field of biopharmaceutical development and regulation.
The NLab discussion group goals include:
- Share learning across industry, academia, and health authorities in Europe in general, and in the Netherlands in particular.
- Generate new scientific and technical insights and solutions for developing biopharmaceutical products in the future.
- Contribute to the expansion of CASSS’ mission, vision, influence, and community in Europe.
Click on the sections below for detailed information:
Navigating Method Comparability and Alternatives: Insights into Ph Eur 5.27 | Utrecht, Netherlands | 15 May 2025 17:30 - 20:30 CET
The NLab Discussion Group is the first CASSS Discussion Group located outside the US and enables the local area community to meet and share ideas and experiences. Register by 12 May 2025.
Location:
Bibliotheek Utrecht Neude, Podium Room
Neude 11, 3512 AE Utrecht Bibliotheek Neude
Navigating Method Comparability and Alternatives: Insights into Ph Eur 5.27 | Utrecht, Netherlands | 15 May 2025 17:30 - 20:30 CET
Join Featured Speakers Tiziana Pacchiarotta, Johnson & Johnson Innovative Medicine, Bruno Spieldenner, European Directorate of the Quality of Medicines & Healthcare (EDQM) Council of Europe. Register by 12 May 2025.
Tiziana Pacchiarotta
Johnson & Johnson Innovative Medicine
Tiziana Pacchiarotta is a scientific manager at Johnson and Johnson Innovative Medicine. She completed her academic career with a PhD at Leiden University Medical Centre before stepping into the pharma industry where she applied analytical strategies to enhance both product and manufacturing knowledge. She has worked with a variety of molecules and therapeutic modalities (e.g. viral vectors, antibodies, gene therapy) from early to late phase and commercial activities.
Bruno Spieldenner
European Directorate of the Quality of Medicines & Healthcare (EDQM) Council of Europe
Bruno Spieldenner is Head of Division chemical substances & products, herbals and general methods in the European Pharmacopoeia Department and has worked for the EDQM, the European Directorate for the Quality of Medicines, of the Council of Europe since 2013. Spieldenner has a MSc in analytical chemistry and spectroscopy form Université Aix-Marseille. He worked for 7 years in the field of mass spectrometry at Hoffmann LaRoche in Basel before joining the EDQM. At the EDQM, among many other things, he was responsible for chapter Ph.Eur. Chapter 5.27 on the comparability of alternative analytical procedures.
Promote Your Participation
Here are some ways you can share your message:
- Follow CASSS on Facebook, X, and LinkedIn. Stay up-to-date on the latest Discussion Group announcements and opportunities. Links can be found in the right column or at the bottom of this page.
- Share your participation via your personal Facebook, X, and LinkedIn accounts. Whether you are a recurring presenter or this is your first time attending, we are grateful to have you join us this year.
- Share the news with your colleagues who run your organization's official social media channels. We are proud to show our community your participation - let your community convey their support too.
- Join our CASSS LinkedIn Group to help create additional discussion before the Discussion Group and beyond about topics of interest with like-minded people. https://www.linkedin.com/groups/2361040/
- Personalize your email signature. Add an image or short message to your default email signature to let your colleagues know you will be attending the Discussion Group.
- Remember to tag CASSS on all social media posts.
If you have any questions about this media kit, please reach out to Renee Olson.
Register Now
Save your spot for the Netherlands Area Biotech (NLab) Discussion Group on 15 May 2025. Register by 12 May 2025.
